DRKS00003072
Recruiting
未知
A Randomized Multicenter Study Comparing the Effectiveness of Hemi- Versus Total Shoulder Arthroplasty in Patients With a Degenerative Joint Disease
AO Foundation0 sites94 target enrollmentJuly 26, 2011
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- M19.91
- Sponsor
- AO Foundation
- Enrollment
- 94
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 years and older
- •Primary or secondary omarthrosis (eg, rheumatoid arthritis, avascular head necrosis)
- •Glenoid morphologic type A1, A2 or B1 according to Walch
- •Ability to understand the content of the patient information / informed consent form and to participate in the clinical investigation
- •Written informed consent
Exclusion Criteria
- •Preoperative:
- •\* Posttraumatic omarthrosis
- •\* Biconcave aspect of glenoid (Walch type B2\)
- •\* Retroversion of glenoid more than 25° (Walch type C)
- •\* Epoca Reko prosthesis
- •\* Humerus fractures
- •\* Patients with a severe systemic disease: class III\-IV according to the American Society of Anaesthesiologists physical status classification (ASA)
- •\* Substance abuse that would preclude reliable assessment
- •\* Pregnancy
- •\* Prisoners
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II) - HIDIT-IITo compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placebo for the treatment with chronic delta hepatits virus.MedDRA version: 9.1Level: LLTClassification code 10047455Term: Viral hepatitis B without mention of hepatic coma, with hepatitis deltaEUCTR2008-005560-13-GRMedizinische Hochschule Hannover70
Completed
Not Applicable
A multicenter randomised study comparing the efficacy of adefovir dipivoxil versus pegylated interferon alpha-2a plus placebo versus adefovir dipivoxil plus peglyated interferon alpha-2a for the treatment of chronic delta hepatitisAdults with chronic delta hepatitisInfections and InfestationsISRCTN83587695Hannover Medical School (MHH) (Germany)69
Active, not recruiting
Phase 1
Treatment of delta hepatitis with pegylated interferon-alfa-2a and tenofovir or placeboTo compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placebo for the treatment with chronic delta hepatits virus.MedDRA version: 15.1Level: LLTClassification code 10047455Term: Viral hepatitis B without mention of hepatic coma, with hepatitis deltaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2008-005560-13-DEMedizinische Hochschule Hannover70
Active, not recruiting
Phase 1
Trial comparing effect of two different dosing regimens of combined medication suppressing immunity on patients with inflammatory disease of cardiac musclePatients with endomyocardial biopsy (EMB) proven inflammatory cardiomyopathy (ICM) defined by EMB established presence of myocardial inflammation and absence of cardiotropic infectious agents established by PCR.Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2012-002828-33-CZFakultní nemocnice u sv. Anny v Brne234
Not yet recruiting
Not Applicable
A multi-centre randomised comparison of the effectiveness and safety of TVT-O and TVT-S.stress incontinence (involunatary leakage of urine during exercise)1004644710029903NL-OMON30427Academisch Medisch Centrum150